Evolve Private Wealth LLC Sells 1,070 Shares of Medpace Holdings, Inc. $MEDP

Evolve Private Wealth LLC reduced its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 28.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,655 shares of the company’s stock after selling 1,070 shares during the quarter. Evolve Private Wealth LLC’s holdings in Medpace were worth $1,275,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. Balboa Wealth Partners lifted its holdings in shares of Medpace by 37.5% in the first quarter. Balboa Wealth Partners now owns 825 shares of the company’s stock worth $396,000 after buying an additional 225 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S grew its position in shares of Medpace by 247.1% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 51,598 shares of the company’s stock valued at $24,777,000 after purchasing an additional 36,731 shares in the last quarter. Hsbc Holdings PLC bought a new position in shares of Medpace in the fourth quarter worth $2,164,000. Corient Private Wealth LLC increased its stake in Medpace by 7.0% in the 4th quarter. Corient Private Wealth LLC now owns 1,830 shares of the company’s stock worth $1,029,000 after acquiring an additional 120 shares during the last quarter. Finally, Worthington Financial Partners LLC bought a new position in shares of Medpace in the fourth quarter worth approximately $1,082,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Weiss Ratings lowered Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Robert W. Baird cut their price objective on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Royal Bank Of Canada reduced their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Finally, BMO Capital Markets decreased their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a report on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $467.08.

Insider Transactions at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 20.50% of the company’s stock.

Medpace Stock Performance

NASDAQ:MEDP opened at $473.48 on Wednesday. The firm has a market cap of $13.52 billion, a PE ratio of 29.76, a price-to-earnings-growth ratio of 2.31 and a beta of 1.18. The business has a 50 day moving average price of $450.81 and a 200-day moving average price of $497.24. Medpace Holdings, Inc. has a fifty-two week low of $305.69 and a fifty-two week high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The firm had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.